We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Sysmex Corporation to Acquire Oxford Gene Technology

By LabMedica International staff writers
Posted on 05 Jun 2017
Sysmex Corporation (Kobe, Japan), an in vitro diagnostic company, has entered into an agreement to acquire molecular genetics company, Oxford Gene Technology (OGT; Begbroke, Oxfordshire, U.K).

Sysmex provides clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. More...
The company is also exploring emerging opportunities in the life science field and aims to leverage its state-of-the-art technologies for cell, gene and protein analysis. OGT provides genetics research solutions to clinical and academic research institutions for high-quality genetic analysis to enable accurate identification and confirmation of the causative variation underlying genetic diseases.

Following its acquisition, OGT will become a wholly owned subsidiary of Sysmex, allowing it to enter the cytogenetics market with the company’s FISH (fluorescence in situ hybridisation) and aCGH (array comparative genomic hybridisation) products. OGT’s innovation and expertise in genetic assays for hematology, solid cancer and rare disease, combined with Sysmex’s expertise in instrument development and in vitro diagnostics will expand the company’s offerings in genomic medicine. For example, the R&D teams from both the companies will collaborate to develop an automated system for FISH testing by combining Sysmex’s automation technology with the high-quality FISH reagent development expertise possessed by OGT. The acquisition will also strengthen Sysmex’s technology base in molecular genetics through OGT’s NGS (next generation sequencing) reagent development capabilities. Moreover, the addition of OGT’s array CGH and NGS capabilities will further expand the opportunities for Sysmex in genetic testing in the field of rare diseases and liquid biopsies.

“We are delighted to become part of such a well-regarded organization and truly believe that the opportunities arising from joining a large global corporation like Sysmex will be transformational for OGT, its employees and customers,” said Professor Sir Edwin Southern, founder of OGT.

“Alongside the exciting product development opportunities already identified, there are a number of beneficial commercial synergies that will expand market access for OGT’s products putting us at the forefront of molecular genetics,” said OGT’s CEO Dr. Mike Evans. “We are looking forward to the next chapter in our development as part of Sysmex.”


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Bordetella Test
Vivalytic Bordetella
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.